Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 55

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Study of telitacicept compared to placebo in adults with moderate to severe systemic lupus erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Remegen Co. Ltd.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:IVX-121
  • Sponsor:AstraZeneca AB

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia

Not yet recruiting

A Study to Assess Effectiveness of IPN60340 with Drug Combination in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ipsen Pharma

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Renal disorder

Not yet recruiting

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.